JP2018507188A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507188A5
JP2018507188A5 JP2017539274A JP2017539274A JP2018507188A5 JP 2018507188 A5 JP2018507188 A5 JP 2018507188A5 JP 2017539274 A JP2017539274 A JP 2017539274A JP 2017539274 A JP2017539274 A JP 2017539274A JP 2018507188 A5 JP2018507188 A5 JP 2018507188A5
Authority
JP
Japan
Prior art keywords
seq
cdr
domain
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507188A (ja
JP6602875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/033099 external-priority patent/WO2016122702A1/en
Publication of JP2018507188A publication Critical patent/JP2018507188A/ja
Publication of JP2018507188A5 publication Critical patent/JP2018507188A5/ja
Application granted granted Critical
Publication of JP6602875B2 publication Critical patent/JP6602875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539274A 2015-01-26 2015-05-29 Dr5結合ドメインを含む多価分子 Expired - Fee Related JP6602875B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107871P 2015-01-26 2015-01-26
US62/107,871 2015-01-26
US201562149139P 2015-04-17 2015-04-17
US62/149,139 2015-04-17
PCT/US2015/033099 WO2016122702A1 (en) 2015-01-26 2015-05-29 Multivalent molecules comprising dr5-binding domains

Publications (3)

Publication Number Publication Date
JP2018507188A JP2018507188A (ja) 2018-03-15
JP2018507188A5 true JP2018507188A5 (enExample) 2018-07-05
JP6602875B2 JP6602875B2 (ja) 2019-11-06

Family

ID=56544108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017539274A Expired - Fee Related JP6602875B2 (ja) 2015-01-26 2015-05-29 Dr5結合ドメインを含む多価分子

Country Status (13)

Country Link
US (1) US10501552B2 (enExample)
EP (1) EP3250601A4 (enExample)
JP (1) JP6602875B2 (enExample)
KR (1) KR20170105622A (enExample)
CN (1) CN107250161A (enExample)
AU (1) AU2015380455A1 (enExample)
CA (1) CA2974807A1 (enExample)
HK (1) HK1247215A1 (enExample)
IL (1) IL253668A0 (enExample)
RU (1) RU2017129236A (enExample)
SG (1) SG11201706024YA (enExample)
TW (1) TWI688572B (enExample)
WO (1) WO2016122702A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
AP2017009823A0 (en) * 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
EP3112381A1 (en) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispecific antibodies for use in cancer immunotherapy
BR112018006578A2 (pt) * 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
US10941204B2 (en) * 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
SG11202003114UA (en) 2017-10-04 2020-05-28 Amgen Inc Transthyretin immunoglobulin fusions
KR102194026B1 (ko) * 2017-12-15 2020-12-22 경북대학교 산학협력단 Trail 수용체에 결합하는 펩타이드 및 이의 용도
CN112243444A (zh) * 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
AU2019315226B2 (en) * 2018-08-03 2025-09-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
CN113260634A (zh) 2018-09-28 2021-08-13 中外制药株式会社 包含改变的抗体可变区的抗原结合分子
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021178569A2 (en) * 2020-03-04 2021-09-10 Regents Of The University Of Minnesota Anti-dr5 polypeptides and methods of use thereof
US20240360228A1 (en) * 2021-05-12 2024-10-31 BioLegend, Inc. Anti-ccr8 antibodies, antigen-binding fragments thereof, and agents and compositions and methods for making and using the same
JP2026502549A (ja) * 2023-01-13 2026-01-23 シャンハイ・カイジン・バイオテクノロジー,リミテッド 多重特異性ポリペプチド複合体
TW202528350A (zh) * 2023-11-10 2025-07-16 大陸商信達生物製藥(蘇州)有限公司 抗dr5和ceacam5的雙特異性抗體及其用途

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US4928535A (en) 1988-10-07 1990-05-29 Oshman's Sporting Goods, Inc. Methods and apparatus for measuring ski boot binding torque
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE19628909C2 (de) 1996-07-18 1999-11-18 Ruesch Willy Ag Verschluß
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
DE69840723D1 (de) 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
US5888553A (en) 1997-04-08 1999-03-30 Infinity, Inc. Non-steroidal anabolic composition
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
MXPA05005726A (es) 2002-11-27 2005-08-16 Irm Llc Metodos y composiciones para inducir apoptosis en celulas de cancer.
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 항체 및 그의 용도
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体(ad5-10)及其制法与用途
JP2008513367A (ja) 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びcd20抗体の使用方法
US20090175854A1 (en) 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006083937A2 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2607056C (en) 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CN105709237A (zh) 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
EP2109668A4 (en) 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー/エス 安定なIgG4抗体
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2010138725A1 (en) 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
WO2011038159A2 (en) 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
KR101508043B1 (ko) 2009-09-29 2015-04-06 로슈 글리카트 아게 이중특이적 사멸 수용체 아고니스트성 항체
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
LT2361936T (lt) 2010-02-25 2016-09-12 Affimed Gmbh Antigeną rišanti molekulė ir jos panaudojimas
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
US20130064838A1 (en) 2010-05-14 2013-03-14 Amgen Inc. Enhanced death receptor agonists
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
EP2596114A4 (en) 2010-07-14 2014-01-08 Amgen Inc IMMUNOGLOBULIN WITH DOMAIN INSERTION
MX339622B (es) * 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
CA2824278C (en) 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
WO2012117336A2 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
ES2703780T3 (es) 2011-05-17 2019-03-12 Trion Res Gmbh Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
US20140155581A1 (en) 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
RU2613368C2 (ru) 2011-07-22 2017-03-16 Аффимед Гмбх Поливалентная антиген-связывающая fv-молекула
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
AU2013216943B2 (en) 2012-02-10 2018-04-19 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
MX350202B (es) * 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
HK1203517A1 (en) 2012-05-24 2015-10-30 F. Hoffmann-La Roche Ag Multispecific antibodies
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
TW201417817A (zh) 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Gsk3抑制劑與抗dr5抗體之組合
CN102924600B (zh) 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
PT2970473T (pt) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2994487B1 (en) * 2013-05-07 2019-10-09 F.Hoffmann-La Roche Ag Trimeric antigen binding molecules
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof

Similar Documents

Publication Publication Date Title
RU2017129236A (ru) Мультивалентные молекулы, содержащие dr5-связывающие домены
JP2018503380A5 (enExample)
JP2020510422A5 (enExample)
JP2021508469A5 (enExample)
JP2021534096A5 (enExample)
JP2020501531A5 (enExample)
JP2020525032A5 (enExample)
JP2017520575A5 (enExample)
JP2022518925A5 (enExample)
JP2021512630A5 (enExample)
JP2013545455A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2019520797A5 (enExample)
JP2014530017A5 (enExample)
JP2017504578A5 (enExample)
IL273424B2 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP2019519199A5 (enExample)
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2021522162A5 (enExample)
JP2019532619A5 (enExample)
JP2013545738A5 (enExample)
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
JP2019501883A5 (enExample)
RU2013125457A (ru) Комбинация антител против с-мет
JP2010532169A5 (enExample)